Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.

Could this be the secret to Pfizer's rebound strategy?

Picking a good dividend stock for your portfolio can be challenging, especially when there are many attractive high-yielding ...

Pfizer is struggling right now, leaving it in the Wall Street doghouse; it won't be there forever.

In the latest close session, Pfizer (PFE) was down 2.75% at $24.04. The stock trailed the S&P 500, which registered a daily ...

Everyone is still arguing about Novo Nordisk (NYSE:NVO | NVO Price Prediction), the Danish obesity juggernaut whose GLP-1 ...

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon trading Friday, extending a ...

Albert Bourla, Pfizer Chairman & CEO, addresses the current state of US vaccinations and the robust growth in Pfizer's ...

Pfizer Inc. (NYSE:PFE) is one of the best dividend stocks to buy, according to hedge funds. On June 24, the US Food and Drug ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

HSBC downgraded Pfizer Inc. PFE on Monday, citing that the company’s near-term re-rating prospects have weakened despite its ...